Siemens' gets US nod for shock wave therapy:
This article was originally published in Clinica
The US FDA has approved Siemens Medical Solutions' SONOCUR basic, a low-energy extracorporeal shock wave therapy system for treating lateral epicondylitis, a condition commonly known as tennis elbow. The company's multicentre, 114-patient, US clinical trial showed that 64% of patients treated with the system achieved at least a 50% reduction in pain at a 12-week follow-up. The trial, said the company, demonstrated that treatment with the device can provide a noninvasive alternative to surgery for patients who have failed to respond to conventional therapies.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.